ERBB2 and congestive heart failure: Thus, it is likely that cardiotoxicity events had been underestimated in many of the RCTs that used anthracycline-based or anti-HER2 therapies, emphasizing the importance of investigating the impact of CHF in retrospective population-based studies [26].